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Additional material for this article may be found online at www.jvascsurg.org. Initiative (VQI) registry data to examine the relationship between OAC use and patency of bypass grafts to infrapopliteal targets. As expected, OACs were more commonly used in higher risk cases. Overall, they found no significant differences in primary graft patency with OAC use, either alone or in combination with aspirin. Subset analysis suggested an association of OAC use with improved secondary patency for prosthetic grafts to tibial targets, at a cost of increased perioperative wound complications. I believe these findings generally confirm the common practice patterns of most U.S. vascular surgeons and suggest the need for further studies. With the growing array of new anticoagulant and antiplatelet therapies, a series of modest-scale prospective studies, perhaps nested within registries like the VQI, is sorely needed to define the best approach. An equally important question is how we are to go about obtaining high-quality evidence, given the costs and complexities of the "gold standard" randomized clinical trial. Why is it even important to accurately measure and compare patency of lower extremity revascularizations? There are two critical reasons. First, it is important to know if the operations we perform and devices we implant function as intended and for how long so that we can have informed risk-benefit discussions with patients across a range of complexity. This information also drives further innovation and improvement. Second, the linkage between vessel patency and patient-oriented end points in peripheral arterial disease is fundamentally important and inadequately understood. The VQI provides a critical tool for vascular research with an infrastructure of data collection across hundreds of institutions. However, it must be further improved to address important questions about procedural durability. Poor compliance with long-term follow-up (eg, one-third of VQI subjects missing 1-year data), lack of consistent protocols for interval graft surveillance across VQI sites, and softer definitions of patency (pulse examination in VQI vs imaging gold standard) raise questions about the accuracy of patency data derived from the VQI at present. Investment in this area would be worthwhile for our specialty and may provide a much needed, cheaper alternative to randomized clinical trials with appropriate study designs.
